Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...

New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis <li /> Vanda expects to immediately ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Following the agreement, Vanda is preparing BLA and MAA applications for the US and EU, with a focus on commercialization. Imsidolimab, a fully humanized IgG4 antibody, is expected to provide ...

Customs duty exemption in Budget for cancer drugs, rare diseases including SMA: Our Bureau, New Delhi Saturday, February 1, 2025, 15:20 Hrs [IST] The 36 life saving drugs and medi ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...